

HEALTHTRUST

September 17, 2020

Hypertensive Disorders of Pregnancy

Frank R. Kolucki, Jr., M.D., FACOG

Chairman of the Department, Obstetrics & Gynecology, Moses Taylor Hospital



Speaker Disclosures

Hypertensive Disorders of Pregnancy

- The presenter has no financial relationships with any commercial interests pertinent to this presentation.
- This program may contain the mention of drugs or brands presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any particular supplier, brand or drug.



Learning Objectives

Hypertensive Disorders of Pregnancy

- Describe the four types of hypertension that can complicate pregnancy
- Discuss maternal and fetal complications that can result from hypertensive disorders of pregnancy
- Outline treatment strategies for the management of hypertensive emergencies in pregnancy
- Identify the benefits of utilizing an evidence-based care team approach to aid patients with hypertensive disorders



Hypertensive Disorders of Pregnancy Treatment of Hypertensive Emergencies: Proper management WILL Prevent Maternal Mortality.



Maternal Mortality, An American Tragedy

YoLanda Mention of Nesmith, NC at her baby shower in 2015



- Uneventful delivery
- Sent home with **dangerously high** blood pressure
- Returned to ER with severe headache and worsening blood pressure
- Made to wait for hours without treatment
- Suffered stroke
- Mother of three daughters died





Maternal Mortality

An American Failure

- America is the most dangerous country in the developed world to give birth
- U.S. ranks 65th in the world regarding maternal death rate
- Only developed nation in the world with increasing rate of maternal mortality
- Increased from 14 to 26.4 / 100,000 Births from 1990–2015
- Occurred during a time of unprecedented medical advancement
- Maternal death classified as "Never Event" by CHS OB Collaborative
- Greatest tragedy in modern medicine

Source: *ACOG Patient Safety and Quality Improvement*. Berg Cl et all Obstet Gynecology 2012 WHO, UNICEF, UNFPA, The World Bank and UNDP. Trends in Maternal Mortality 1990-2013:2014



Maternal Morbidity is Extreme

- Shock
- Acute Kidney Injury
- Pulmonary Embolism
- Acute Respiratory Distress Syndrome (ARDS)
- Myocardial Infarction
- Sepsis
- Increased by 45% from 2006 -2015
- Affects 80,000 mothers per year

Sources: Callaghan, Wm. et al. Obstet, Gynecology, 2012. K Fingar et al Trands and Disparities in Delivery Hospitalizations Involving Severe Maternal Morbidity, 2006-2015





Maternal Fetal Medicine

- Antenatal Steroids
- Antibiotics for Premature preterm rupture of membranes
- Magnesium for Neuroprotection
- 17 Hydroxyprogesterone for Preterm Birth Prevention
- Fetal Therapy for Twin-Twin Transfusion Syndrome, Neonatal Alloimmune Thrombocytopenia, & Neural Tube Defect
- Head/body cooling for Hypoxic Ischemic Encephalopathy



Clear Need for Action

Where is the "M" in Maternal-Fetal Medicine?

Source: D'Alton, ME. et al. Where is the "M" in Maternal-Fetal medicine? Obstet Gynecol. 2010; 116: 1401-1404

CLINICAL OPINION

OBSTETRICS

Putting the "M" back in maternal-fetal medicine

Mary E. D'Alton, MD; Clarissa A. Bonanno, MD; Richard L. Berkowitz, MD; Haywood L. Brown, MD; Joshua A. Copel, MD; F. Gary Cunningham, MD; Thomas J. Garite, MD; Larry C. Gilstrap III, MD; William A. Grobman, MD, MBA; Gary D. V. Hankins, MD; John C. Hauth, MD; Brian K. Iriye, MD; George A. Macones, MD, MSCE; James N. Martin Jr, MD; Stephanie R. Martin, DO; M. Kathryn Menard, MD, MPH; Daniel F. O'Keefe, MD; Luis D. Pacheco, MD; Laura E. Riley, MD; George R. Saade, MD; Catherine Y. Spong, MD

Although maternal death remains rare in the United States, the rate has not decreased for 3 decades. The rate of severe maternal morbidity, a more prevalent problem, is also rising. Rise in maternal age, in rates of obesity, and in cesarean deliveries as well as more pregnant women with chronic medical conditions all contribute to maternal mortality and morbidity in the United States. We believe it is the responsibility of maternal-fetal medicine (MFM) subspecialists to lead a national effort to decrease maternal mortality and morbidity. In doing so, we hope to reestablish the vital role of MFM subspecialists to take the lead in the performance and coordination of care in complicated obstetrical cases. This article will summarize our initial recommendations to enhance MFM education and training, to establish national standards to improve maternal care and management, and to address critical research gaps in maternal medicine.

Key words: maternal-fetal medicine, maternal-fetal medicine education, maternal-fetal medicine research, maternal morbidity, maternal mortality

With a seminal article presented in the *Lancet* less than 25 years ago, Allan Rosenfield and Deborah Maine¹ galvanized the international public health movement to reduce maternal Inspired by their message and their leg-

mortality has not decreased for 3 decades.^{3,4} There continue to be dramatic disparities in health care outcomesincluding marked differences in maternal mortality rates-between different socioeconomic and racial groups.³ Moreover, severe maternal morbidity is a much more prevalent problem than maternal death, affecting tens of thousands of women each year.^{6,7}

Maternal mortality and morbidity rates may even be rising due to a number of reasons. Delaying childbearing and assisted reproductive technology has allowed more women of advanced maternal age to conceive. Obesity has also become a national epidemic and is responsible for increasing rates of hypertension, diabetes, and other chronic diseases affecting pregnancy.⁸ The rising cesarean delivery rate has increased the incidence of placenta accreta, a diagnosis associated with a high risk of postpartum

From the Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY (Drs D'Alton, Bonanno, Berkowitz); Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC (Dr Brown); Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT (Dr Copel); Department of Obstetrics and Gynecology, University of Texas Southwestern Medical School, Dallas, TX (Dr Cunningham); Department of Obstetrics and Gynecology, School of Medicine at University of California. Invine, Irvine, CA (Dr Garite); Department of Obstetrics, Gynecology, Feinberg School of Medicine, Northwestern University, Of California. Invine, Irvine, CA (Dr Garite); Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL (Dr Grobma); Departments of Obstetrics-Gynecology and Anesthesiology, University of Texas Medical Branch, School of Medicine, Galveston, TX (Dr Hankins, Pacheco, and Saade); Department of Obstetrics and Gynecology, University of Alabama School of Medicine, Galveston, TX (Dr Hankins, Pacheco, and Saade); Department of Obstetrics and Gynecology, University of Alabama School of Medicine, Galveston, TX (Dr Hankins, Pacenter, Las Vegas, NV (Dr trive); Department of Obstetrics and Gynecology, University of Maississippi Medical School, Jackson, MS (Dr JN Martin Jr); Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX (Dr SM Martin), Dr Shearting, Pacenter, Las Vegas, MC (Dr Kacefee); Department of Obstetrics and Gynecology, Bully College of Medicine, Houston, TX (Dr SM Martin), Dr Shearting, Paceford), Baylor College of Medicine, Houston, TX (Dr SM Martin), Dr Department of Obstetrics and Gynecology, Haver Alexies, Houston, MS (Dr SM Martin), Dr (Dr O'Keefe); Department of Obstetrics and Gynecology, Harvard Medical School, Boston, MA (Dr Riley); and *Eurice Kennedy Striver* National Institute of Child Health and Human Development, Bethesed, MD (Dr Sono

Received Sept. 27, 2012; revised Nov. 16, 2012; accepted Nov. 28, 2012.

Dr D'Alton delivered the keynote address, "Putting the 'M' Back in Maternal-Fetal Medicine," at the 2012 annual meeting of the American Gynecological and Obstetrical Society. Her address had the same title and content as this manuscript. Dr Spong, as a federal employee, cannot assign copyright. Dr Gilstrap is the executive director of the American Board of Obstetrician Gynecologists, which accredits the maternal-fetal medicine fellowships. No other author reports a conflict of interest.

Reprints: Mary E. D'Alton, MD, Division of Matemal-Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 622 W. 168 St., 16th Floor, New York, NY 10032. md511@columbia.edu.

0002-9378/\$36.00 • © 2013 Mosby, Inc. All rights reserved. • http://dx.doi.org/10.1016/j.ajog.2012.11.041

442 American Journal of Obstetrics & Gynecology JUNE 2013



National Focus

R³ **Report** Requirement, Rationale, Reference A complimentary publication of The Joint Commission

Issue 24, August 21, 2019

Published for Joint Commission-accredited organizations and interested health care professionais, *R3 Report* provides the rationals and references that The Joint Commission employs in the development of new requirements. While the standards manuals also may provide a rationale, *R3 Report* goes into more depth, providing a rationale statement for each element of performance (IP). The references provide the evidence that supports the requirement. *R3 Report* may be reproduced if credited to The Joint Commission. Sign up for <u>email</u> delivery.

Provision of Care, Treatment, and Services standards for maternal safety

Effective July 1, 2020, 13 new elements of performance (EPs) will be applicable to Joint Commission-accredited hospitals. These new requirements are within the Provision of Care, Treatment, and Services (PC) chapter at PC.06.01.01 and PC.06.01.03 and are designed to improve the quality and safety of care provided to women during all stages of pregnancy and postpartum. The United States ranks 65th among industrialized nations in terms of maternal death.¹ Because of worsening maternal morbidity and mortality, The Joint Commission evaluated expert literature to determine what areas held the most potential impact. The literature review revealed that prevention, early recognition, and timely treatment for maternal hemorrhage and severe hypertension/preeclampsia had the highest impact in states working on decreasing maternal complications. This approach was supported by a technical advisory panel assembled by The Joint Commission, resulting in the development of EPs that focus on these complications.

Engagement with stakeholders, customers, and experts

In addition to an extensive literature review and public field review, The Joint Commission obtained expert guidance from the following groups:

- Technical Advisory Panel (TAP) of subject matter experts from various health care and academic organizations and professional associations from the maternal health field.
- Standards Review Panel (SRP) comprised of clinicians and administrators who provided a "boots on the ground" point of view and insights into the practical application of the proposed standards.

The prepublication version of the maternal safety standards will be available online until June 30, 2020. After July 1, 2020, please access the new requirements in the E-dition or standards manual.

1. Centers for Disease Control and Prevention, Reproductive Health, Pregnancy Mortality Surveillance System webpage Page last reviewed: June 4, 2019. Accessed Aug. 20, 2019.

Standard PC.06.01.03: Reduce the likelihood of harm related to maternal severe hypertension/preeclampsia.

Requirement	EP 1: Develop written evidence-based procedures for measuring and remeasuring blood pressure. These procedures include criteria that identify patients with severely elevated blood pressure.		
Rationale	Procedures should address appropriate blood pressure measurement, including cuff size, proper patient positioning, and frequency of measurement. Inaccurate measurement can lead to a mother not receiving proper treatment and being discharged with elevated blood pressure. Untreated hypertension can lead to morbidities or even death. Criteria for what constitutes a severely elevated blood pressure should be established by the organization utilizing current recommendations from national organizations.		
Reference	Nathan H, et al. "Blood Pressure Management in Pregnancy." Royal College of Obstetricians and Gynaecologists. 2015;17:91-98.		
Requirement	EP 2: Develop written evidence-based procedures for managing pregnant and postpartum patients with severe hypertension/preeclampsia that includes the following:		
	 The use of an evidence-based set of emergency response medications that are stocked and immediately available on the obstetric unit 		
	 The use of seizure prophylaxis 		
	 Guidance on when to consult additional experts and consider transfer to a higher level of care 		
	 Guidance on when to use continuous fetal monitoring 		
	Guidance on when to consider emergent delivery		
	 Criteria for when a team debrief is required 		
	Note: The written procedures should be developed by a multidisciplinary team that includes		

Note: The written procedures should be developed by a multide ciplinary team that includes

© 2019 The Joint Commission





National Focus

R³ Report | Requirement, Rationale, Reference Issue 24, Aug. 21, 2019 Page | 5

Provision of Care, Treatment, and Services standards for maternal safety

The Joint Commission

	representation from obstetrics, emergency department, anesthesiology, nursing, laborator
Bartin and	and pharmacy.
Rationale	Studies have shown that delays in the diagnosis and treatment of severe
	hypertension/preeclampsia and receipt of suboptimal treatment of severe
	hypertension/preeclampsia are linked with adverse maternal outcomes. Having clear
	procedures in place and educating staff around these procedures should decrease failures
	to recognize and treat severe hypertension/preeclampsia.
Reference	American College of Obstetricians and Gynecologists. "Emergent Therapy for Acute-Onset,
	Severe Hypertension During Pregnancy and the Postpartum Period. ACOG Committee Opinion No. 767." Obstetrics & Gynecology. 2019;133:e174-180.
	American College of Obstetricians and Gynecologists. "Task Force on Hypertension in
	Pregnancy. Hypertension in Pregnancy Task Force Report." DOI: 10.1097/01.A0G.0000437382.03963.88
	Troiano NH and Witcher PM. "Maternal Morbidity in the United States: Classification on
	Causes, Preventability and Critical Care Obstetric Implications." Journal of Perinatalogy &
	Neonatal Nursing. 2018;32(3):222-231.
Requirement	EP 3: Provide role-specific education to all staff and providers who treat pregnant/
	postpartum patients about the hospital's evidence-based severe hypertension/preeclamp
	procedure. At a minimum, education occurs at orientation, whenever changes to the
	procedure occur, or every two years.
	Note: The emergency department is often where patients with symptoms or signs of sever
	hypertension present for care after delivery. For this reason, education should be provided
	to staff and providers in emergency departments regardless of the hospital's ability to
	provide labor and delivery services.
Rationale	Decreasing the blood pressure through rapid recognition and treatment has been shown to
	decrease maternal morbidity and mortality. It is imperative to provide education for staff a
	providers on how to measure accurate blood pressures, recognize severe hypertension/
	preeclampsia, and provide evidence-based treatments to lower blood pressure in a safe ar
	timely manner. Although not required, in situ simulations that allow staff to practice
	organizational procedures in actual clinical settings are encouraged.
Reference	American College of Obstetricians and Gynecologists. "Task Force on Hypertension in
	Pregnancy. Hypertension in Pregnancy Task Force Report." DOI:
	10.1097/01.AOG.0000437382.03963.88
	Druzin JL, et al. Preeclampsia Toolkit – "Improving Health Care Response to Preeclampsia
	California Toolkit to Transform Maternity Care (2014)." Developed under contract #11-
	10006 with the California Department of Public Health; Maternal, Child and Adolescent
	Health Division. Published by the California Maternal Quality Care Collaborative. 2013.
Requirement	EP 4: Conduct drills at least annually to determine system issues as part of ongoing quality
	improvement efforts. Severe hypertension/preeclampsia drills include a team debrief.
Rationale	Multidisciplinary drills give an organization the opportunity to practice skills and identify
	system issues in a controlled environment. It is crucial to have members from as many
	disciplines as possible available during drills to truly be able to test each level of the
	emergency and identify areas of improvement. Organizations should assess their level of
	proficiency to determine the frequency drills should be performed; organizations that have
	reached a high level of mastery may need less frequent drills.
Reference	American College of Obstetricians and Gynecologists. "Preparing for Clinical Emergencies i
	Obstetrics and Gynecology." ACOG Committee Opinion No. 590. Obstetrics & Gynecology.
	2014;123:722-725.
	Kyryabina E, et al. "What is the Value of Health Emergency Preparedness Exercises? A
	Scoping Review Study." International Journal of Disaster Risk Reduction. 2017;21:274-28



National Focus

6	Provision of Care, Treatment, and Services standards for maternal safety	
	Providers." MedEdPORTAL. 2018;14:1-8.	
Requirement	EP 5: Review severe hypertension/preeclampsia cases that meet criteria established by the hospital to evaluate the effectiveness of the care, treatment, and services provided to the patient during the event.	
Rationale	Continuous feedback loops are imperative for organizations to find errors and improve skills to ensure that patients are receiving the highest level of care. Root cause analysis, apparent-cause analysis, or similar tools to review the care in a rigorous, psychologically safe environment is critical to identify successes and opportunities for improvement in a wa that creates a culture of safety and empowers staff to design safe and effective procedures and processes.	
Reference	Callaghan WM, et al. "Facility-Based Identification of Women with Severe Maternal Morbidity: It is Time to Start." Obstetrics & Gynecology. 2014;123:978-981.	
	Kilpatrick SJ, et al. "Standardized Severe Maternal Morbidity Review: Rationale and Process." Obstetrics & Gynecology. 2014;124:361-366.	
Requirement	 EP 6: Provide printed education to patients (and their families including the designated support person whenever possible). At a minimum, education includes: Signs and symptoms of severe hypertension/preeclampsia during hospitalization that alert the patient to seek immediate care Signs and symptoms of severe hypertension/preeclampsia after discharge that alert the patient to seek immediate care When to schedule a post-discharge follow-up appointment 	
Rationale	Maternal mortality reviews have shown that some patients with severe hypertension/ preeclampsia due after discharge because they were unaware of which symptoms to watch for and when to seek care urgently. Women should understand their severe hypertension/ preeclampsia diagnosis and inform healthcare providers of their pregnancy history when the seek care after discharge to ensure correct diagnosis and treatment.	
Reference	Brousseau CE, et al. "Emergency Department Visits for Postpartum Hypertension." Hypertension in Pregnancy. 2017;36(2):212-216.	
	American College of Obstetricians and Gynecologists. "Optimizing Postpartum Care." ACOG Committee Opinion No. 736. Obstetrics & Gynecology. 2018;131:e140-e150.	
	Suplee PD, et al. "Discharge Education on Maternal Morbidity and Mortality Provided by Nurses to Women in the Postpartum Period. <i>Journal of Obstetric, Gynecologic and Neonatal</i> <i>Nursing</i> . 2016;45:8994-904.	
	Suplee PD, et al. "Improving Postpartum Education About Warning Signs of Maternal Morbidity and Mortality. Journal of Obstetric, Gynecologic and Neonatal Nursing. 2016:20:552-567.	

Not a complete literature review.







Maternal Mortality

An American Tragedy 50% of Maternal Deaths are Preventable

Regarding **deaths** associated with **hypertension:** 50%–60% of patients had a significant chance of a different outcome if managed more effectively.

Source: D'Alton ME, Main EK, Menard MK, Levy BS. The national partnership for maternal safety. Obstet Gynecol 2014;123:973–7



Confidential: Not for distribution

Maternal Mortality

Three Significant Etiologies/Three Opportunities/Three High Value Targets

- Hemorrhage
- Hypertension / Preeclampsia / Eclampsia
- Thromboembolism

Source: D'Alton ME, Main EK, Menard MK, Levy BS. The national partnership for maternal safety. Obstet Gynecol 2014;123:973-7



Healthcare is a Team Sport

HealthTrust Team Members

- Nursing
- Pharmacy
- Laboratory Medicine
- Physicians
- Administrators



Maternal mortality and morbidity crisis cannot be fixed by obstetricians alone.

Need your help in your sphere of influence.



Chronic Hypertension

- Blood pressure is \geq 140/90 prior to pregnancy or prior to 20 weeks gestation
- Definition of hypertension may be in flux per American College of Cardiology and American Heart Association
- Elevated blood pressure \geq 12 weeks post partum



Preeclampsia

- New onset of hypertension (HTN) blood pressure is ≥ 140/90
- Proteinuria 300 mg or more per 24 hr. urine collection
- Or, HTN and significant end-organ disease with or without proteinuria after 20 weeks gestation in a previously normotensive patient.

Risk Factors for Preeclampsia Nulliparity Multifetal gestations Preeclampsia in a previous pregnancy Chronic hypertension Pregestational diabetes Gestational diabetes Thrombophilia Systemic lupus erythematosus Prepregnancy body mass index greater than 30 Antiphospholipid antibody syndrome Maternal age 35 years or older Kidney disease Assisted reproductive technology Obstructive sleep apnea



Eclampsia

• The development of eclampsia can lead to the evolution of grand mal seizures in the absence of other pathologic neurologic process associated with seizures.

Sources: *Working group report on high blood pressure in pregnancy* NIH 2000. ACOG Task Force 2013





Preeclampsia (With or Without Severe Features)

Severe Features:

- Systolic $BP \ge 160$ or Diastolic $BP \ge 110$
- Platelets < 100,000 per mm3
- Abnormal liver function test ALT/AST ≥ 2X normal
- Renal insufficiency (creatinine level ≥ 1.2 or doubling of base line)
- Pulmonary edema
- New onset of cerebral or visual changes
- Right upper quadrant, epigastric pain

Source: Working group report on high blood pressure in pregnancy NIH 2000 / ACOG Task Force 2013





Chronic Hypertension with Superimposed Preeclampsia

Diagnosis can be challenging.

- New onset proteinuria
- End-organ dysfunction status post 20 weeks gestation
- One or both could occur

Example:

- New onset proteinuria or sudden increase protein
- Sudden increase BP formally controlled on medication
- Platelets < 100,000 per mm3
- Increased liver function tests (ALT/AST)
- Central Nervous System changes

RULE OUT THE WORST FIRST. Practitioners should think superimposed preeclampsia first, not simply an exacerbation of chronic hypertension.



Gestational Hypertension

- Hypertension without proteinuria or other signs or symptoms of preeclampsia or associated end-organ dysfunction
 - May evolve into preeclampsia
 - May become severe and life threatening
 - Some experts believe that gestational hypertension and preeclampsia are part of the same spectrum of pathophysiology

Source: Working group report on high blood pressure in pregnancy NIH 2000 / ACOG Task Force 2013



Why Is It important

- Hypertensive disorder of pregnancy is a significant cause of maternal morbidity and mortality worldwide
- Greater than 80,000 maternal deaths annually
- 1 preeclamptic death every 7 minutes
- #3 cause of fetal mortality largely because of iatrogenic prematurity
- Accounts for greater than 5% of all United States fetal deaths over 20 weeks

Source: Ananth, C.V. and Smulian, J.C. (2018). Epidemiology of Critical Illness in Pregnancy. In Critical Care Obstetrics



Maternal Mortality Reviews

- Failure by healthcare providers to realize that preeclampsia is **MULTISYSTEMIC IN NATURE**.
 - This leads to a late or missed diagnosis.
- Failure to recognize that preeclampsia is **ALWAYS PROGRESSIVE**.
 - Rate of progression varies.
 - Providers must keep tempo with disease progression.
 - (Don't let it get ahead of you)
 - The only cure is delivery.
- May worsen post partum (be vigilant).



Maternal Mortality Reviews

Nearly 50% of preeclamptic / eclamptic deaths were determined to have a strong or good chance to improve patient outcomes.

Maternal death **CAN** be prevented if health care teams are vigilant to ensure an accurate diagnosis and rapid treatment of hypertensive emergencies/eclampsia.



Hypertensive Disorders of Pregnancy – Types of Hypertension

CHRONIC HYPERTENSION	 SBP ≥ 140 or DBP ≥ 90 Pre-pregnancy or < 20 weeks
GESTATIONAL HYPERTENSION	 SBP ≥140 or DBP ≥ 90 > 20 weeks Absence of Proteinuria or systemic signs/symptoms
PREECLAMPSIA - ECLAMPSIA	 SBP ≥ 140 or DBP ≥ 90 Proteinuria with our without signs/symptoms Presentation of signs symptoms/lab abnormalities but no proteinuria *Proteinuria not required for diagnosis eclampsia seizure in setting of preeclampsia
CHRONIC HYPERTENSION + SUPERIMPOSED PREECLAMPSIA	
PREECLAMPSIA WITH SEVERE FEATURES	 Two severe BP values (SBP ≥ 160 or DBP ≥ 110) obtained 15-60 minutes apart Persistent oliguria <500ml/24 hours Progressive renal insufficiency Unremitting headache/visual disturbances Pulmonary edema Epigastric/RUQ pain LFTs > 2x normal Platelets < 100K HELLP syndrome *5 gr of proteinuria no longer criteria for severe preeclampsia

26 Source: Maternal Safety Bundle for Severe Hypertension in Pregnancy, ACOG 2017 Confidential: Not for distribution



Accurate Diagnosis is Key

Blood Pressure Evaluation

- Patient should be sitting upright, legs uncrossed, back and arms supported, and rested for 5 minutes
- Use correct cuff size
- The middle of the cuff should be on the upper arm at the level of the heart's atrium
- No recent tobacco or caffeine use
- Repeat in 5 minutes if elevated
- Left lateral position falsely lowers blood pressure **do not rely on this BP!**



Spectrum Pathophysiology is Large & Complex

- Can affect many organ systems
- Caregivers need high index of suspicion
- This condition is often rapidly progressive and fulminant



Preeclampsia

Cardiovascular Manifestations

- Vascular constriction due to increased vascular reactivity
- Hemoconcentration (vascular tank not full); increased concentration of cells and blood components resulting from loss of fluid to the extravascular space
- Resultantly, mothers don't tolerate hemorrhage well



Sources: Foley et al Obstetric Intensive Care Manual 2004

Preeclampsia

Hematologic Manifestations

- Hemoconcentration Fluid transverses into third space because of damage to endothelium of blood vessels
- Leads to the telltale signs of edema, primarily the hands and face
- Thrombocytopenia (Platelets < 100,000 per mm3)
- Hemolysis of red blood cells leads to
 - Increased lactic acid dehydrogenase (LDH)
 - Elevated bilirubin
 - Schistocytes (fragmented part of a red blood cell) on peripheral smear
 - May lead to anemia (vs. Hemoconcentration)
- Severe disease may be associated with Disseminated Intravascular Coagulation (DIC)
- Part of the death quadriad: Hypothermia, Acidemia, DIC & Electrolyte aberration





Preeclampsia

Renal Manifestations

- Vasoconstriction leads to poor perfusion of kidneys, resulting in a decreased glomerular filtration rate (GFR).
- GFR normally increases up to 50% in pregnancy
- Creatinine level rarely greater than 0.8 mg/dL (Red Flag)
- Creatinine level ≥ 1.2 mg/dL = severe disease
- Pathology leads to oliguria (< 500 cc /24° or < 30cc per hour for 2 consecutive hours)
- Potential acute kidney injury

Sources: Foley, et al. Obstetric Intensive Care Manual 2004



Preeclampsia

Hepatic Manifestations

- Damage to hepatocytes leads to the release of ALT/AST
- Severe disease can lead to subcapsular hematoma (associated with epigastric RUQ pain)
 - Don't miss this complaint!
- Liver rupture leads to hemorrhagic shock with predisposition to multisystem organ failure and very high mortality rate



Preeclampsia

Central Nervous System Manifestations

- Severe unrelenting headache is a harbinger of bad things to come
 - Any headache warrants further investigation!
- Eclamptic seizures
 - major cause of maternal mortality worldwide
 - may be attributed to hypertensive encephalopathy or ischemia from vasoconstriction (possibly from cerebral edema)



Preeclampsia

Central Nervous System Manifestations

- Hemorrhagic stroke (thrombotic stroke less likely)
 - Major cause of maternal death in the United States
 - Largely preventable with timely antihypertensive therapy and magnesium sulfate
- UK initiative demonstrated significant decrease in maternal morbidity and mortality



Preeclampsia

Seizure Prevention/Treatment

- Magnesium sulfate is the drug of choice.
- If magnesium sulfate is contraindicated (myasthenia gravis, hypocalcemia, moderate to severe renal failure, cardiac ischemia, heart block, myocarditis) or recalcitrant seizures, caregivers should consider:
 - Lorazepam (Ativan)
 - Diazepam (Valium)
 - Levetiracetam (Keppra)
 - Neuromuscular blockade and intubation



Preeclampsia

Central Nervous System Manifestations

- Be aware of the warning signs/symptoms
 - Headache
 - Scotomata
 - Photopsia (flashes of light)
 - Blurred vision
 - Change in mental status
 - Transient loss of vision (Amaurosis)
- Headache (80%) & visual changes (45%) are the most common prodromal neurologic symptoms associated with eclampsia, regardless of the degree of hypertension both antepartum and postpartum.



Preeclampsia

Pulmonary Manifestations

- Pulmonary edema/congestive heart failure/cyanosis
- Acute respiratory failure
- Acute respiratory distress syndrome (ARDS)



Preeclampsia

HELLP Syndrome

- Pathophysiology is in a class of it's own
- Often progressive and fulminant if not diagnosed and treated in a timely fashion
- Risk of maternal death is 1%
- H Hemolysis

 $LDH \ge 600 \text{ U/L}$ bilirubin $\ge 1.2 \text{ mg/dl}$

- EL Elevated liver enzymes ALT AST > 2X normal LDH 600 U/L
- **LP** Low platelets Platelets < 100,000 per mm³

*Presentation may be atypical (e.g. low platelets with mild elevation LFTs).



Preeclampsia

HELLP Syndrome

Often associated with severe pathology and extreme maternal morbidity.

- Disseminated Intravascular Coagulation (DIC) 15-30 %
- Pulmonary edema 8%
- Acute kidney injury- 3%
- Stroke 1%
- Acute respiratory distress syndrome (ARDS) 1%
- Subcapsular liver hematoma or liver rupture




Focus on Eclampsia

Eclampsia

- Rate is 0.05 0.1%
- Major cause of maternal and perinatal morbidity and mortality
- Can occur:
 - Antepartum 50%
 - Intrapartum 25%
 - Postpartum 25%








v10.21.13



APPENDIX A: SAMPLE MANAGEMENT OF ECLAMPSIA ALGORITHM

Management of Eclampsia





What Constitutes a Hypertensive Emergency in Pregnancy?

- Persistent, severe HTN that can occur antepartum, intrapartum or post partum.
- Defined: 2 severe blood pressure readings SBP \geq 160 OR DBP \geq 110 taken 15 minutes apart.
- Severe values need not be consecutive.

(Only need to have one critical blood pressure reading to have a stroke)

*Controlling blood pressure is optimal intervention to prevent maternal death due to stroke in patient with preeclampsia/eclampsia.





When to Treat:

- SBP ≥ 160 **OR** DBP ≥ 110
- If persistent for 5-15 minutes or more, begin treatment ASAP - The goal is for initiation of treatment within 15 minutes (ACOG within 60 minutes)
- Rapid treatment is emerging as an important quality metric in obstetrics
- Goal is not normotension. May lead to placental hypoperfusion with resultant fetal distress
- Goal is 140 150 / 90 100 mm Hg



FIRST LINE THERAPIES

- Intravenous labetalol
- Intravenous hydralazine
- Oral nifedipine

(More rapid and effective than Labetalol)

Magnesium sulfate not recommended as antihypertensive agent

- Should be used for: seizure prophylaxis and controlling seizures in eclampsia
- IV bolus of 4-6 grams in 100 ml over 20 minutes, followed by IV infusion of 1-2 grams per hour. Continue for 24 hours postpartum
- If no IV access, 10 grams of 50% solution IM (5 g in each buttock)
- Contraindications: pulmonary edema, renal failure, myasthenia gravis

Anticonvulsants (for recurrent seizures or when magnesium is C/I):

- Lorazepam: 2-4 mg IV x 1, may repeat x 1 after 10-15 min
- Diazepam: 5-10 mg IV every 5-10 min to max dose 30 mg
- Phenytoin: 15-20 mg/kg IV x 1, may repeat 10 mg/kg IV after 20 min if no response. Avoid with hypotension, may cause cardiac arrhythmias.
- Keppra: 500 mg IV or orally, may repeat in 12 hours. Dose adjustment needed if renal impairment.

*There may be adverse effects and additional contraindications. Clinical judgement should prevail

Safe Motherhood Initiative



HEALTHTRUST

Hypertensive Emergency Checklist

HYPERTENSIVE EMERGENCY:

- Two severe BP values (≥160/110) taken 15-60 minutes apart. Values do not need to be consecutive.
- May treat within 15 minutes if clnically indicated
- Call for Assistance
- Designate:
 - 🔵 Team leader
 - Checklist reader/recorder
 - 🔵 Primary RN
- 🔲 Ensure side rails up
- Ensure medications appropriate given patient history
- Administer seizure prophylaxis (magnesium sulfate first line agent, unless contraindicated)
- Antihypertensive therapy within 1 hour for persistent severe range BP
- Place IV; Draw preeclampsia labs
- Antenatal corticosteroids (if <34 weeks of gestation)
- Re-address VTE prophylaxis requirement
- Place indwelling urinary catheter
- Brain imaging if unremitting headache or neurological symptoms
- Debrief patient, family, and obstetric team

"Active asthma" is defined as:

- A symptoms at least once a week, or
- use of an inhaler, corticosteroids for asthma during the pregnancy, or
- © any history of intubation or hospitalization for asthma.

REVISED JULY 2017

MAGNESIUM SULFATE

Contraindications: Myasthenia gravis; avoid with pulmonary edema, use caution with renal failure

IV access:

 Load 4-6 grams 10% magnesium sulfate in 100 mL solution over 20 min
 Label magnesium sulfate; Connect to labeled infusion pump
 Magnesium sulfate maintenance 1-2 grams/hour

No IV access:

10 grams of 50% solution IM (5 g in each buttock)

ANTIHYPERTENSIVE MEDICATIONS

For SBP \geq 160 or DBP \geq 110 (See SMI algorithms for complete management when necessary to move to another agent after 2 doses.)

- Labetalol (initial dose: 20mg); Avoid parenteral labetalol with active asthma, heart disease, or congestive heart failure; use with caution with history of asthma
- Hydralazine (5-10 mg IV* over 2 min); May increase risk of maternal hypotension
- Oral Nifedipine (10 mg capsules); Capsules should be administered orally, not punctured or otherwise administered sublingually

* Maximum cumulative IV-administered doses should not exceed 220 mg labetalol or 25 mg hydralazine in 24 hours


Note: If first line agents unsuccessful, emergency consult with specialist (MFM, internal medicine, OB anesthesiology, critical care) is recommended

ANTICONVULSANT MEDICATIONS

For recurrent seizures or when magnesium sulfate contraindicated

- Lorazepam (Ativan): 2-4 mg IV x 1, may repeat once after 10-15 min
- Diazepam (Valium): 5-10 mg IV q 5-10 min to maximum dose 30 mg

Checklists help in multi-step process where the omission of any step can lead to patient harm.



Safe Motherhood Initiative






REVISED JULY 2017

Labetalol Algorithm

EXAMPLE

Trigger: If severe elevations (SBP ≥160 or DBP ≥ 110) persist* for 15 min or more **OR** If two severe elevations are obtained within 15 min and tx is clinically indicated





REVISED JULY 2017

Hydralazine Algorithm

EXAMPLE

Trigger: If severe elevations (SBP ≥160 or DBP ≥ 110) persist* for 15 min or more OR If two severe elevations are obtained within 15 min and tx is clinically indicated



ACOG w References w OBTERNANE wo GTNEORLOGITS Durnet




Oral Nifedipine Algorithm

REVISED JANUARY 2018

EXAMPLE

Trigger: If severe elevations (SBP ≥160 or DBP ≥ 110) persist* for 15 min or more **OR** If two severe elevations are obtained within 15 min and tx is clinically indicated



Oral Nifedipine superior to oral Labetalol because of more rapid onset of actions



Source: ACOG Safe Motherhood Initiative 2017

Eclampsia Checklist

Call for Assistance

🗌 Designate

- 🔘 Team leader
- O Checklist reader/recorder
- O Primary RN

🗌 Ensure side rails up

- Protect airway and improve oxygenation:
 - Maternal pulse oximetry
 - Supplemental oxygen (100% non-rebreather)
 - Lateral decubitis position
 - Bag-mask ventilation available
 Suction available
- Continuous fetal monitoring
- Place IV; Draw preeclampsia labs
- Ensure medications appropriate given patient history
- 🗌 Administer magnesium sulfate
- Administer antihypertensive therapy if appropriate
- 🗌 Develop delivery plan, if appropriate
- Debrief patient, family, and obstetric team

* "Active asthma" is defined as:

- (A) symptoms at least once a week, or
- use of an inhaler, corticosteroids for asthma during the pregnancy, or
- © any history of intubation or hospitalization for asthma.

REVISED JULY 2017



MAGNESIUM SULFATE

Contraindications: Myasthenia gravis; avoid with pulmonary edema, use caution with renal failure

IV access:

Load 4-6 grams 10% magnesium sulfate in 100 mL solution over 20 min

Label magnesium sulfate; Connect to labeled infusion pump
 Magnesium sulfate maintenance 1-2 grams/hour

No IV access: 10 grams of 50% solution IM (5 g in each buttock)

ANTIHYPERTENSIVE MEDICATIONS

For SBP \geq 160 or DBP \geq 110 (See SMI algorithms for complete management when necessary to move to another agent after 2 doses.)

- Labetalol (initial dose: 20mg); Avoid parenteral labetalol with active asthma, heart disease, or congestive heart failure; use with caution with history of asthma
- Hydralazine (5-10 mg IV* over 2 min); May increase risk of maternal hypotension
- Oral Nifedipine (10 mg capsules); Capsules should be administered orally, not punctured or otherwise administered sublingually

* Maximum cumulative IV-administered doses should not exceed 220 mg labetalol or 25 mg hydralazine in 24 hours

Note: If persistent seizures, consider anticonvulsant medications and additional workup

ANTICONVULSANT MEDICATIONS

For recurrent seizures or when magnesium sulfate contraindicated

- Lorazepam (Ativan): 2-4 mg IV x 1, may repeat once after 10-15 min
- Dlazepam (Vallum): 5-10 mg IV q 5-10 min to maximum dose 30 mg

FOR PERSISTENT SEIZURES

- Neuromuscular block and intubate
- Obtain radiographic imaging

ICU admission

Consider anticonvulsant medications

Checklists help in multistep process where the omission of any step can lead to patient harm.



Source: California Maternal Quality Care Collaborative - ACOG Safe Motherhood Initiative 2017



Don't be Afraid to Call for Help - "Circle the Wagons"

- Critical Care
- Internal Medicine
- Anesthesia
- Emergency Medicine
- Maternal Fetal Medicine



Mentor's Pearl

Being an obstetrician is much like serving two masters simultaneously whose goals are diametrically opposed to each other.



Mother

• Severe Morbidity or Mortality




Baby

 Iatrogenic Prematurity with Resultant Morbidity & Mortality

Senefit to baby must outweigh the risk to mother.





😝 HEALTHTRUST

Maternal

- Uncontrolled severe-range blood pressures (persistent systolic blood pressure 160 mm Hg or more or diastolic blood pressure 110mm Hg or more, not responsible to antihypertensive medication
- Persistent headaches, refractory to treatment
- Epigastric pain or right upper pain unresponsive to repeat analgesics
- Visual disturbances, motor deficit or altered sensorium
- Stroke
- Myocardial infarction
- HELLP syndrome
- New or worsening renal dysfunction (serum creatinine greater than 1.1 mg/dL or twice baseline)
- Pulmonary edema
- Eclampsia
- Suspected acute placental abruption or vaginal bleeding in the absence of placenta previa

Fetal

- Abnormal fetal testing
- Fetal death
- Fetus without expectation for survival at the time of maternal diagnosis (e.g. extreme prematurity)
- Persistent, reversed end-diastolic flow in the umbilical artery

Abbreviation: HELLP, hemolysis, elevated liver enzymes and low platelet count

*In some cases, a course of antenatal steroids can be considered depending on gestational age and maternal severity of illness.

* Neonates requiring imminent delivery may benefit from exposure to first dose of betamethasone.

Sources :ACOG Practice Bulletin Number 202, January 2019. Balogun OA, Sibai BM. Counseling, management and outcome in women with severe preeclampsia at 23–28 weeks' gestation. Clin Obstet Gynecol 2017; 60: 183-9



Recommendations for the Timing of Delivery When Conditions Complicate Pregnancy

Maternal Conditions – Hypertensive Disorders of Pregnancy	General Timing	Suggested Specific Timing
Chronic hypertension: isolated, uncomplicated, controlled, not requiring medications	Early term/full term	$38\frac{0}{7}$ to $39\frac{6}{7}$ weeks of gestation
Chronic hypertension: isolated, uncomplicated, controlled, on medications	Early term/full term	$37\frac{1}{7}$ to $39\frac{6}{7}$ weeks of gestation
Chronic hypertension: difficult to control (requiring frequent medication adjustments)	Late preterm/early term	$36\frac{0}{7}$ to $37\frac{6}{7}$ weeks of gestation
Gestational Hypertension, without severe-range blood pressure	Early term	37 $\frac{0}{7}$ weeks or at diagnosis if diagnosed later
Gestational Hypertension with severe-range blood pressures	Late preterm	$34 \frac{0}{7}$ weeks or at diagnosis if diagnosed later
Preeclampsia without severe features	Early term	$37\frac{0}{7}$ weeks or at diagnosis if diagnosed later
Preeclampsia with severe features, stable maternal & fetal conditions, after fetal viability (includes superimposed)	Late preterm	$34 \frac{0}{7}$ weeks or at diagnosis if diagnosed later
Preeclampsia with severe features, unstable or complicated, after fetal viability (includes superimposed and HELLP)	Soon after maternal stabilization	Soon after maternal stabilization
Preeclampsia with severe features, before viability	Soon after maternal stabilization	Soon after maternal stabilization
Sources: American College of Obstetricians. Volume 133, No. 2 Februa Committee Opinion, Late-Preterm and Farly-Preterm Deliveries	Confidential: Not for distribution Publishe	d by Wolters Kluwer Health, Inc.

56 Committee Opinion, Late-Preterm and Early-Preterm Deliveries.



COMPLICATIONS & ESCALATION PROCESS

MATERNAL (pregnant or postpartum)

- CNS (seizure, unremitting headache, visual disturbance)
- Pulmonary edema or cyanosis
- Epigastric or right upper quadrant pain
- Impaired liver function
- Thrombocytopenia
- Hemolysis
- Coagulopathy
- Oliguria *<30 ml/hr for 2 consecutive hours

Prompt evaluation and communication: If undelivered, plan for delivery

ACCOG MERICIN CONCRESS ar OBSTETRICIANS wo CONECOLOCISTS District

🚔 HEALTHTRUST

FETAL

Abnormal fetal tracing

• IUGR

Safe Motherhood Initiative

MONITORING CHANGE OF STATUS

Once patient is stabilized, consider:

SEIZURE PROPHYLAXIS

Magnesium sulfate (if not already initiated)

TIMING & ROUTE OF DELIVERY

 \circ Eclampsia \rightarrow Delivery after stabilization

○ HELLP/Severe preeclampsia/
 Chronic hypertension + superimposed
 preeclampsia → Vaginal delivery, if attainable in
 reasonable amount of time

 $\circ \geq 34$ weeks \rightarrow Deliver

MATERNAL BP

- Continue control with oral agents
- Target range of 140-150/90-100

IF PRETERM (<34 WKS) & EXPECTANT MGMT PLANNED

- Antenatal corticosteroids
- Subsequent pharmacotherapy
- HELLP (Gestational age of fetal viability to 33 6/7 wks)
- Delay delivery for 24-48 hours if maternal and fetal condition remains stable
- Contraindications to delay in delivery for fetal benefit of corticosteroids:
 - Uncontrolled hypertension
 - Eclampsia
 - Pulmonary edema
 - Suspected abruption placenta
 - Disseminated intravascular coagulation,
 - Nonreassuring fetal status
 - Intrauterine fetal demise



🚔 HEALTHTRUST

POSTPARTUM SURVEILLANCE

Necessary to prevent additional morbidity as preeclampsia/eclampsia can develop postpartum

INPATIENT

- Measure BP every 4 hours after delivery until stable
- Do not use NSAIDs for women with elevated BP (current controversy)
- Do not discharge patient until BP is well controlled for at least 24 hours

OUTPATIENT

- For pts with preeclampsia, visiting nurse evaluation recommended:
- ✓ Within 3-5 days
- Again in 7-10 days after delivery (earlier if persistent symptoms)

* Preeclampsia/eclampsia can occur 4-6 weeks. California Maternal Quality Care Collaborative

ANTIHYPERTENSIVE THERAPY

- Recommended for persistent postpartum HTN: SBP ≥ 150 or DBP ≥ 100 on at least two occasions at least 4 hours apart
- Persistent SBP ≥ 160 or DBP ≥ 110 should be treated within 1 hour



Safe Motherhood Initiative

Source: ACOG Safe Motherhood Initiative 2017 Clinical Pearl Patients often get worse before they get better.

Preeclampsia can commonly manifest itself as a post partum event



Postpartum Preeclampsia Checklist EMERGENCY DEPARTMENT

TRIAGE PATIENTS LESS THAN 6 WEEKS POSTPARTUM AS FOLLOWS:

Core evaluation and assessment

- If BP ≥ 160/110 or 140/90 with:
- Unremitting headaches
 Visual disturbance
 Epigastric pain
- Begin stabilization
- Call for Obstetric consult immediately
- OBS contact documented
- Call MFM/MICU consult immediately for refractory blood pressure
- Labs should include:
 - CBC
 - PT
 - PTT
 - Fibrinogen
 - CMP
 - Uric Acid
 - Hepatic function panel
 Type and Screen
- Initiate Intravenous Access
- Assess neurologic status
 LOC/arousal/orientation/behavior
 Deep tendon reflexes
 - Speech
- Assess vital signs including oxygen saturation
- Assess complaints and report; unremitting headaches, epigastric pain, visual disturbances, speech difficulties, lateralizing neuro signs
- Place Foley catheter
- Strict I&O report output less than 30 ml/hr for 2 hours
- Plan brain imaging studies if:
 - Unremitting headache
 - Focal signs and symptoms
 Uncontrolled high blood pressure
 - · oncontrolled high blood pre
 - Lethargy
 - Confusion
 - Seizures
 - Abnormal neurologic examination

INITIAL MEDICATIONS

- Load 4-6 grams 10% magnesium sulfate in 100 ml solution IV over 20 minutes
- Magnesium sulfate on infusion pump
- Magnesium sulfate and pump labeled
- Magnesium sulfate 10 grams of 50% solution IM (5 grams in each buttock) if no IV access
- Magnesium sulfate maintenance 1-2 grams/hour continuous infusion

Contraindications: pulmonary edema, renal failure, myasthenia gravis

If magnesium sulfate is contraindicated: Keppra 500 mg PO or IV every 12 hours

ANTIHYPERTENSIVE MEDICATIONS

 Labetalol (20, 40, 80, 80 mg IV* over 2 minutes, escalating doses, repeat every 10 minutes or 200 mg orally if no IV access); avoid in asthma or heart failure, can cause neonatal bradycardia

 Hydralazine (5-10 mg IV* over 2 minutes, repeat in 20 minutes until target blood pressure is reached)

 Repeat blood pressure every 10 minutes during administration

* Maximum cumulative IV administered doses should not exceed 25 mg hydralazine; 220 mg labetalol in 24 hours. Checklists help in multi-step process where the omission of any step can lead to patient harm.

Source: ACOG Safe Motherhood Initiative 2017

IN AMERICAN CONCLESS or OBSTETERCIANS AND CIVILIZIOLOCIDIS Distriction



DISCHARGE PLANNING

All patients receive information on preeclampsia:

- ✓ Signs and symptoms
- ✓ Importance of reporting information to health care provider as soon as possible
- ✓ Culturally-competent, patient-friendly language

All new nursing and physician staff receive information on hypertension in pregnancy and postpartum

FOR PATIENTS WITH PREECLAMPSIA

- ✓ BP check recommended 72 hours after delivery
- ✓ Outpatient surveillance (visiting nurse evaluation) recommended:
 - $\,\circ\,$ Within 3-5 days
 - Again in 7-10 days after delivery (earlier if persistent symptoms)





Safe Motherhood Initiative

Preventive Strategies for Reducing the Risk of Hypertensive Disorders of Pregnancy/Aspirin Therapy

Level of Risk	Risk Factors	Recommendation	
High [†]	 History of preeclampsia, especially when accompanied by an adverse outcome 	Recommend low-dose aspirin if the patient has one or more of these high-risk factors	
	 Multifetal gestation 		
Chronic hypertension			
	• Type 1 or 2 diabetes		
	Renal disease		
	 Autoimmune disease (ie, systemic lupus erythematosus, the antiphospholipid syndrome) 		
Moderate [‡]	Nulliparity	Consider low-dose aspirin if the patient ha	
	• Obesity (body mass index greater than 30)	more than one of these moderate-risk factors [§]	
	• Family history of preeclampsia (mother or sister)		
	• Sociodemographic characteristics (African American race, low socioeconomic status)		
	 Age 35 years or older 		
	• Personal history factors (eg, low birth weight or small for gestational age, previous adverse pregnancy outcome, more than 10-year pregnancy interval)		
Low	 Previous uncomplicated full-term delivery 	Do not recommend low-dose aspirin olog	

* Based on good and consistent scientific evidence (Level A)

Sources: ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstetrics & Gynecology133(1):e1-e25, January 2019.





READINESS

Every Unit

- Standards for early warning signs, diagnostic criteria, monitoring and treatment
 of severe preeclampsia/eclampsia (include order sets and algorithms)
- Unit education on protocols, unit-based drills (with post-drill debriefs)
- Process for timely triage and evaluation of pregnant and postpartum women with hypertension including ED and outpatient areas
- Rapid access to medications used for severe hypertension/eclampsia: Medications should be stocked and immediately available on L&D and in other areas where patients may be treated. Include brief guide for administration and dosage.
- System plan for escalation, obtaining appropriate consultation, and maternal transport, as needed

RECOGNITION & PREVENTION

Every Patient

- Standard protocol for measurement and assessment of BP and urine protein for all pregnant and postpartum women
- Standard response to maternal early warning signs including listening to and investigating patient symptoms and assessment of labs (e.g. CBC with platelets, AST and ALT)
- Facility-wide standards for educating prenatal and postpartum women on signs and symptoms of hypertension and preeclampsia





PATIENT SAFETY BUNDLE

Hypertension

RESPONSE

- Every case of severe hypertension/preeclampsia
- Facility-wide standard protocols with checklists and escalation policies for management and treatment of:
- Severe hypertension
- Eclampsia, seizure prophylaxis, and magnesium over-dosage
- Postpartum presentation of severe hypertension/preeclampsia
- Minimum requirements for protocol:
- Notification of physician or primary care provider if systolic BP =/> 160 or diastolic BP =/> 110 for two measurements within 15 minutes
- After the second elevated reading, treatment should be initiated ASAP (preferably within 60 minutes of verification)
- Includes onset and duration of magnesium sulfate therapy
- Includes escalation measures for those unresponsive to standard treatment
- Describes manner and verification of follow-up within 7 to 14 days postpartum
- Describe postpartum patient education for women with preeclampsia
- Support plan for patients, families, and staff for ICU admissions and serious complications of severe hypertension

REPORTING/SYSTEMS LEARNING

Every unit

- Establish a culture of huddles for high risk patients and post-event debriefs to identify successes and opportunities
- Multidisciplinary review of all severe hypertension/eclampsia cases admitted to ICU for systems issues
- Monitor outcomes and process metrics

Note: "Facility-wide" indicates all areas where pregnant or postpartum women receive care. (E.g. L&D, postpartum critical care, emergency department, and others depending on the facility).

© 2015 American College of Obstetrictans and Gynecologists. Permission is hereby granted for duplication and distribution of this document, in its entirety and without modification, for solely non-commercial activities that are for educational, quality improvement, and patient safety purposes. All other uses require written permission from ACOG.

Standardization of health care processes and reduced variation has been shown to improve outcomes and quality of care. The Council on Patient Safety in Women's Health Care disseminates patient safety bundles to help facilitate the standardization process. This bundle reflects emerging clinical, scientific, and patient safety advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Although the components of a particular bundle may be adapted to local resources, standardization within an institution is strongly encouraged.

The Council on Patient Safety in Women's Health Care is a broad consortium of organizations across the spectrum of women's health for the promotion of safe health care for every woman.


May 2015



Assessment Question 1

Which type of hypertensive disorder can complicate pregnancy and features a new onset of hypertension with blood pressure 140/90 or greater and proteinuria of 300mg or more in a 24 hour urine collection?

- a. Chronic hypertension
- b. Gestational hypertension
- c. Preeclampsia
- d. Malignant hypertension






Assessment Question 1 Correct Response

Which type of hypertensive disorder can complicate pregnancy and features a new onset of hypertension with blood pressure 140/90 or greater and proteinuria of 300mg or more in a 24 hour urine collection?

- a. Chronic hypertension
- b. Gestational hypertension
- c. Preeclampsia
- d. Malignant hypertension






Assessment Question 2

Maternal and fetal complications that can result from hypertensive disorders of pregnancy include which of the following?

- a. Intrauterine growth restriction (IUGR)
- b. Eclamptic seizures
- c. Hemorrhagic stroke
- d. All of the above






Assessment Question 2 Correct Response

Maternal and fetal complications that can result from hypertensive disorders of pregnancy include which of the following?

- a. Intrauterine growth restriction (IUGR)
- b. Eclamptic seizures
- c. Hemorrhagic stroke
- d. All of the above






Assessment Question 3

Which of the following is a first line treatment strategy in the management of hypertensive emergencies in pregnancy?

- a. Oral labetalol
- b. Oral hydralazine
- c. Oral nifedipine
- d. Magnesium sulfate






Assessment Question 3 Correct Response

Which of the following is a first line treatment strategy in the management of hypertensive emergencies in pregnancy?

- a. Oral labetalol
- b. Oral hydralazine
- c. Oral nifedipine
- d. Magnesium sulfate






Assessment Question 4

How does an evidence-based care team approach improve outcomes in patients with hypertensive disorders of pregnancy?

- a. Timely, accurate diagnosis
- b. Minimize delays in critical processes
- c. Enhance communication between team members
- d. All of the above






Assessment Question 4 Correct Response

How does an evidence-based care team approach improve outcomes in patients with hypertensive disorders of pregnancy?

- a. Timely, accurate diagnosis
- b. Minimize delays in critical processes
- c. Enhance communication between team members
- d. All of the above





Maternal Mortality – An American Failure

Conclusion:

- Severe uncontrolled hypertension is deadly.
- Eclampsia is deadly.
- Diagnose quickly and accurately.
- Clinical deterioration can be rapid and fulminate.
- Timely, accurate diagnosis and rapid treatment will save lives.
- Be vigilant for complications.
- Healthcare is a TEAM sport.
- Get the word out!



It is incumbent on all healthcare professionals to take the responsibility to begin adopting new approaches, new tools and new thinking to reverse the rates of maternal mortality and morbidity in the U.S.

Source: Foley et al Obstetric Intensive Care Manual 2004



References

- Young A. Hospitals know how to protect mothers. They just aren't doing it. USA Today. <u>https://www.usatoday.com/in-depth/news/investigations/deadly-deliveries/2018/07/26/maternal-mortality-rates-preeclampsia-postpartum-hemorrhage-safety/546889002/</u>. Accessed September 10, 2020.
- 2. Berg Cl et al. ACOG Patient Safety and Quality Improvement. Obstet Gynecol 2012.
- 3. WHO, UNICEF, UNFPA, The World Bank and UNDP. Trends in Maternal Mortality 1990-2013:2014.
- 4. Callaghan W et al. Obstet Gynecol 2012.
- 5. K Fingar et al. Trends and Disparities in Delivery Hospitalizations Involving Severe Maternal Morbidity, 2006-2015.
- 6. D'Alton ME, et al. Where is the "M" in Maternal-Fetal medicine? Obstet Gynecol 2010; 116: 1401-1404.
- 7. The Joint Commission. R3 Report. 2019.
- 8. D'Alton ME, Main EK, Menard MK, Levy BS. The national partnership for maternal safety. Obstet Gynecol 2014;123:973–7.
- 9. Working group report on high blood pressure in pregnancy NIH 2000.
- 10. ACOG Task Force 2013.
- 11. ACOG Practice Bulletin Number 202 January 2019.
- 12. Ananth CV and Smulian JC. Epidemiology of Critical Illness in Pregnancy. In Critical Care Obstetrics 2018.
- 13. ACOG. Maternal Safety Bundle for Severe Hypertension in Pregnancy. 2017.
- 14. Foley et al. Obstetric Intensive Care Manual. 2004



References

- 15. California Maternal Quality Care Collaborative. Eclampsia Algorithm.
- 16. ACOG. Safe Motherhood Initiative. 2017.
- 17. California Maternal Quality Care Collaborative. Suspected Preeclampsia Algorithm.
- 18. Balogun OA, Sibai BM. Counseling, management and outcome in women with severe preeclampsia at 23–28 weeks' gestation. *Clin Obstet Gynecol* 2017; 60: 183-9.
- 19. American College of Obstetricians. Volume 133, No. 2 February 2019.
- 20. ACOG. Committee Opinion, Late-Preterm and Early-Preterm Deliveries.



. . . Thank you. . . Frank Kolucki fkolucki@mth.org

